top of page

【Portfolio】Anji Pharma Acquires Global Development Rights for ApoE Mimetic Peptides from LipimetiX

封面logo2.35-1-anji.png

View source version on https://anjipharma.com/news/capstone-therapeutics-announces-results-of-special-shareholder-meeting-and-a-license-transfer-royalty-agreement-and-exit-from-the-pharmaceutical-development-business/

18 Feb 2021

LipimetiX Development, Inc.(“LipimetiX”), an approximately 62%-owned subsidiary of Capstone Therapeutics, recently entered into a License Transfer and Royalty Agreement (the “Agreement”) with Anji Pharmaceuticals, Inc (“Anji Pharma”). The Agreement transfers all rights to the technology for AEM-28 and certain of its analogs licensed by LipimetiX under an Exclusive License Agreement (the “License”) with the University of Alabama at Birmingham Research Foundation. Anji Pharma previously sublicensed the same technology for the Territory of China, Hong Kong and Taiwan. This Agreement conveys worldwide rights to the technology to Anji Pharma, which will conduct all development activities and assume all development obligations under the License. In return, LipimetiX will receive upfront cash payments and a royalty on future commercial sales. Any cash and future royalty consideration received will first pay off remaining LipimetiX liabilities, and amounts owed to the Company; and then, as described below, be paid directly to LipimetiX shareholders.

To read more, click here.

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.

bottom of page